In a report released yesterday, Mayank Mamtani from B.Riley Financial maintained a Hold rating on Madrigal Pharmaceuticals (MDGL – Research ...

B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Altimmune (ALT – Research Report) yesterday and set a price target of ...

In a report released yesterday, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on ImmunoPrecise Antibodies (IPA – Research ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Ironwood Pharma (IRWD – Research Report) and Centessa Pharmaceuticals (CNTA – Research Report).

See the top stocks recommended by analysts >> Nektar Therapeutics (NKTR) B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Nektar Therapeutics today and set a price target of $4.00.

In a report released today, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on TG Therapeutics (TGTX – Research Report), with a price target of $38.00. The company’s shares ...

B.Riley Financial analyst Mayank Mamtani reiterated a Buy rating on Cassava Sciences (NASDAQ:SAVA) on Tuesday, setting a price target of $108, which is approximately 55.62% above... Investing.com ...

Brad Hogg didn't mince his words as he spoke about Mayank Yadav's injury and the seeming influence of IPL on young fast bowlers. Mayank Yadav became a household name during the 2024 edition of the ...

When Mayank Yadav burst onto the scene for Lucknow Super Giants he did rattle the batters with his high pace. However, his career has been curtailed by injuries. In the recently concluded Border ...

Earlier, Mayank Yadav also missed the South Africa's tour due to back injury and also didn't play the Syed Mushtaq Ali Trophy and Vijay Hazare Trophy. India's Mayank Yadav set to miss the white ...